CLINICAL TRIALS PROFILE FOR MICARDIS

All Clinical Trials for MICARDIS

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00034840 ↗	Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose	Completed	Bayer	Phase 4	2001-10-01	The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period.
NCT00034840 ↗	Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose	Completed	GlaxoSmithKline	Phase 4	2001-10-01	The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period.
NCT00034840 ↗	Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose	Completed	Boehringer Ingelheim	Phase 4	2001-10-01	The primary objectives are to demonstrate that MICARDIS® (telmisartan) is statistically superior to Diovan® (valsartan) in reducing diastolic blood pressure (DBP) following a missed dose at the end of a 6 to 8-week treatment period as measured by the 24-hour ABPM mean and to demonstrate that MICARDIS® is statistically superior to Diovan® in reducing DBP during the last 6-hours of the 24-hour dosing interval as measured by ABPM following a dose of active study medication at the end of a 6 to 8-week treatment period.
NCT00133185 ↗	A Randomized, Double-blind, Parallel-group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg (Micardis Plus) in Comparison With Losartan 50mg Plus Hydrochlorothiazide 12.5mg in Taiwanese Patients With Mild to	Completed	Boehringer Ingelheim	Phase 3	2004-03-01	The primary objective of this trial is to compare the efficacy and safety of telmisartan 40 mg/hydrochlorothiazide 12.5mg (Micardis Plus) with that of losartan 50 mg/hydrochlorothiazide 12.5 mg, a reference AIIA combined with diuretic, in Taiwanese patients with mild to moderate hypertension.
NCT00144222 ↗	Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan Monotherapy	Completed	Boehringer Ingelheim	Phase 3	2005-01-01	The objective of this trial is to demonstrate that the fixed dose combination of telmisartan 40 mg and HCTZ 12.5 mg is superior to the monocomponent of telmisartan (Micardis, Gliosartan, Kinzal, Kinzalmono, Predxal, Pritor, Samertan, Telmisartan) 40 mg in patients with essential hypertension who fail to respond adequately to telmisartan monotherapy.
NCT00146289 ↗	The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects	Completed	Boehringer Ingelheim	Phase 2	2005-02-01	The primary objective of this study is to determine whether MICARDIS® improves insulin sensitivity in overweight or obese, non-diabetic, normotensive subjects.
NCT00147264 ↗	Telmisartan-Induced Reduction in Intra-Myocellular Lipids Trial	Completed	Boehringer Ingelheim	Phase 3	2004-04-01	The purpose of this study is to determine whether telmisartan and/or a low-glycemic index diet are effective in reducing intra-myocellular lipid (muscle fat) content.

Clinical Trial Conditions for MICARDIS

Condition Name

Condition Name for MICARDIS
Intervention	Trials
Hypertension	53
Healthy	3
Diabetic Nephropathies	2
Metabolic Syndrome X	2

Condition MeSH

Condition MeSH for MICARDIS
Intervention	Trials
Hypertension	50
Essential Hypertension	6
Kidney Diseases	3
COVID-19	2

Clinical Trial Locations for MICARDIS

Trials by Country

Trials by Country for MICARDIS
Location	Trials
United States	271
Canada	45
Korea, Republic of	9
Australia	7
France	6

Trials by US State

Trials by US State for MICARDIS
Location	Trials
California	12
Illinois	11
Texas	10
Georgia	10
Pennsylvania	9

Clinical Trial Progress for MICARDIS

Clinical Trial Phase

Clinical Trial Phase for MICARDIS
Clinical Trial Phase	Trials
Phase 4	18
Phase 3	12
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for MICARDIS
Clinical Trial Phase	Trials
Completed	61
Recruiting	7
Active, not recruiting	2

Clinical Trial Sponsors for MICARDIS

Sponsor Name

Sponsor Name for MICARDIS
Sponsor	Trials
Boehringer Ingelheim	52
Bayer	3
GlaxoSmithKline	2

Sponsor Type

Sponsor Type for MICARDIS
Sponsor	Trials
Industry	66
Other	33
NIH	1